Fox Run Management L.L.C. Buys Shares of 3,989 Vaxcyte, Inc. (NASDAQ:PCVX)

Fox Run Management L.L.C. purchased a new position in Vaxcyte, Inc. (NASDAQ:PCVX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,989 shares of the company’s stock, valued at approximately $327,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Whipplewood Advisors LLC bought a new position in Vaxcyte in the fourth quarter worth about $28,000. Smartleaf Asset Management LLC raised its position in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after purchasing an additional 260 shares during the period. Blue Trust Inc. lifted its holdings in shares of Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after purchasing an additional 371 shares during the last quarter. Assetmark Inc. boosted its position in Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after purchasing an additional 775 shares during the period. Finally, Nomura Asset Management Co. Ltd. acquired a new position in Vaxcyte during the 3rd quarter valued at approximately $92,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total value of $692,080.00. Following the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,472,066.41. The trade was a 6.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Teri Loxam sold 6,250 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now owns 7,175 shares of the company’s stock, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,250 shares of company stock valued at $3,840,018 over the last three months. Company insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PCVX shares. Guggenheim reiterated a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Price Performance

NASDAQ PCVX opened at $68.56 on Thursday. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The firm has a market capitalization of $8.83 billion, a PE ratio of -14.90 and a beta of 1.02. The company’s 50 day simple moving average is $80.72 and its 200 day simple moving average is $93.16.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.